FDA advisory panel declines to support a controversial Alzheimer’s treatment
The drug, aducanumab, is made by pharmaceutical company Biogen
![Biogen headquarters](https://i0.wp.com/www.sciencenews.org/wp-content/uploads/2020/11/110620_LS_alz-drug_feat.jpg?fit=1028%2C579&ssl=1)
Pharmaceutical company Biogen is developing a drug that promises to slow, but not stop or reverse, the march of Alzheimer’s in the brain. But not all scientists are convinced that the drug works.
Kristoffer Tripplaar/Alamy